An interventional study of Probiotic and Placebo in Obesity and Food Addiction, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing probiotic in Obesity — 9 open to participants now, 12 under way, none of them phase 3. Probiotic · Obesity.
Among the 33 studies testing probiotic in Obesity, this one is the 7th largest by enrollment, is one of 4 that started in 2023, is one of 28 with no phase, and was the 17th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →9 of the 33 studies testing probiotic in Obesity are open now, in 6 countries. Recruiting first, the newest first:
Wecare Probiotics Co., Ltd. · Sites in China
Ages 18–40 · Women only · Healthy volunteers
Chinese Academy of Sciences · Sites in China
Ages 20–50 · Healthy volunteers
Celia Bañuls · Sites in Spain
Ages 18–65
Lallemand Health Solutions · Sites in France
Ages 50–70 · Healthy volunteers
The Archer-Daniels-Midland Company · Sites in Korea, Republic of
Ages 19–75 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2023.
This study's enrollment of 106 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 76 across the 33 interventional studies. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 33 have an industry lead sponsor. The 10 most frequent:
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
32 studies in Obesity by University of California, Los Angeles: 4 open now, 5 under way, none of them phase 3. Of 24 finished, 5 (21%) have results posted.
Among the 32 studies in Obesity by University of California, Los Angeles, this one is the 10th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2023, is one of 23 with no phase, and was the 30th registered.
University of California, Los Angeles’s Obesity studies by the year they started, since 2004.
5 of the studies testing probiotic in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07507929Wecare Probiotics Co., Ltd.Probiotic for Weight Management in Overweight and Obese Adults | 2026-12-01 |
| NCT06989177Chinese Academy of SciencesProbiotic Intervention on Body Weight | 2026-12-30 |
| NCT06912100University of ConnecticutL. Acidophilus (Strain TW01) on Gut Health, Body Composition, and Inflammation | 2026-12-31 |
| NCT07505212Prairie View A&M UniversityEffects of Gallotannins on the Gut Microbiome and How it Affects Inflammatory Markers Among Obese Individuals. | 2027-02-14 |
| NCT06901739Celia BañulsTherapeutic Potential of a Synbiotic to Improve Mental Health in Subjects With Obesity. | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 33 studies testing probiotic in Obesity, from their registry updates:
Among University of California, Los Angeles’s 32 in Obesity:
This tab as a report to print or save as PDF → With an account.
The current standard of care for obesity is the optimal management of comorbid conditions such as diabetes and hyperlipidemia, and counseling on diet, weight loss, or increased physical activity programs. However, lifestyle, diet, and behavioral interventions may provide between 7-10% reduction in initial weight and even fewer with long-term weight loss. In severely obese patients (BMI>40 or BMI>35 with comorbidities), bariatric surgery is also a potential treatment, but there is a high barrier for patients to undergo surgery for weight loss. These barriers include an aversion to major abdominal surgery, long recovery time, potential risk of vitamin deficiency, and risk for abdominal pain. For these reasons, there is a paramount need for other treatments for obesity and for food addiction.
The current standard of care for obesity and food addiction is difficult to implement and lacks sustained efficacy. Most struggle to complete treatment, lose minimal weight, lack sustained weight loss, and engage in the well-known "YoYo" diet phenomenon. While bariatric surgery is currently the only effective treatment for obesity, there are several barriers associated with it such as eligibility requirements, invasiveness, difficult recovery, and cost making it not readily available for everyone. Some approved medications that help with obesity, such as orlistat, lorcaserin, or naltrexone-bupropion, have not been widely adopted by providers or patients due to their limited responses and adverse side effects. Probiotic cocktails have shown to be safe with little to no side effects. Preclinical models of probiotics demonstrate the ability to curb obesity in animal models. Therefore, a probiotic that is able to show significant weight loss along with lifestyle modifications would be highly adopted and desirable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Probiotic
Dietary Supplement: Placebo
Dietary Supplement taken once daily for 3 months (90 days).
Dietary Supplement taken once daily for 3 months (90days).
Differences in metabolite concentrations pre & post intervention - Stool
Measurement of metabolomics via stool specimen.
Time frame: Collected three times by the participant at home, once at baseline (week 0), once at mid-study (week 6), and once at the final 3month appointment (week 12).
Differences in metabolite concentrations pre & post intervention - Blood
Measurement of metabolomics via blood specimen.
Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (week 6), and once at the final 3month appointment (week 12).
Differences in microbiome levels pre & post intervention - Stool
16S RNA sequencing to measure microbiome levels via stool specimen.
Time frame: Collected three times by the participant at home, once at baseline (week 0), once at mid-study (week 6), and once at the final 3month appointment (week 12).
Differences in microbiome levels pre & post intervention - Blood
16S RNA sequencing to measure microbiome levels via blood specimen.
Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (week 6), and once at the final 3month appointment (week 12).
Differences in microbiome levels pre & post intervention - Stool
Shotgun metagenomics, sequencing to measure microbiome levels via stool specimen.
Time frame: Collected three times by the participant at home, once at baseline (week 0), once at mid-study (week 6), and once at the final 3month appointment (week 12).
Differences in microbiome levels pre & post intervention - Blood
Shotgun metagenomics, sequencing to measure microbiome levels via blood specimen.
Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (week 6), and once at the final 3month appointment (week 12).
Differences in Subjective Stress Response - PANAS
Between and within group differences on the negative affect subscale from the Brief Positive Affect and Negative Affect Scale (PANAS) before and after the laboratory stress tasks. PANAS scores can range from 10-50 for both the positive and negative affect, with the lower scores representing lower levels of positive/negative affect, and higher scores representing higher levels of positive/negative affect.
Time frame: Lasting approximately 10 minutes, measured pre & post the laboratory stress tasks, at baseline (week 0) and end of study (week 12).
Changes in Autonomic Measures - Heart Rate Variability
Between and within group differences in overall average change in heart rate variability pre and post each laboratory stress task.
Time frame: Measured throughout each laboratory stress task during the baseline (week 0) and end of study (week 12) visits, lasting approximately 1 hour.
Changes in Autonomic Measures - Skin Conductance
Between and within group differences in overall average change in skin conductance response (SCR) pre and post each laboratory stress task measured using BIOPAC GSR (galvanized skin response) 100C system. Measured in Hz.
Time frame: Measured throughout each laboratory stress task during the baseline (week 0) and end of study (week 12) visit. Lasting approximately 1 hour.
Changes in Autonomic Measures - Diastolic & Systolic blood pressure
Between and within group differences in overall average change in both diastolic and systolic blood pressure pre and post each laboratory stress task.
Time frame: Measured throughout each laboratory stress task during the baseline (week 0) and end of study (week 12) visit. Lasting approximately 1 hour.
Differences in Attention/Executive Function - Color Stroop
Between and within group differences on the time it takes to complete the Color Stroop attention/executive function lab stress task.
Time frame: Lasting approximately 10minutes, measured at baseline (week 0) and end of study (week 12).
Differences in Attention/Executive Function - Trails A & B
Between and within group differences on the time it takes to complete the Trails A \& B attention/executive function lab stress task.
Time frame: Lasting approximately 10minutes, measured at baseline (week 0) and end of study (week 12).
Differences in Emotional Arousal System - IAPS task
Between and within group differences in valence and emotional arousal ratings during the International Affective Picture System (IAPS) task.
Time frame: Lasting approximately 15minutes, measured at baseline (week 0) and end of study (week 12).
Systolic and Diastolic Blood Pressure
Measurement of the pressure of circulating blood at rest
Time frame: Measured three times, once at each in-clinic appointment (week 0, week 6, week 12).
Anthropometrics - BMI
Measurement of height(in) \& weight(lbs), used to calculate body mass index (BMI).
Time frame: Measured three times, once at each in-clinic appointment (week 0, week 6, & week 12)
Questionnaire Data - Diet
Use of validated surveys including the Food Frequency questionnaire, Food Choice Questionnaire.
Time frame: Self-Reported by the participant at home, collected 3 times (1) before beginning the dietary supplement, (2) at least 1 week before the mid-study appointment, and (3) within 1 week of finishing the 90-day dietary supplement.
Questionnaire Data
Use of validated surveys to assess ingestive behaviors, stress, health, physical activity, etc.
Time frame: Self-Reported by the participant at home, collected 3 times (1) before beginning the dietary supplement, (2) at least 1 week before the mid-study appointment, and (3) within 1 week of finishing the 90-day dietary supplement.
Anthropometrics - waist and hip circumference
Measurement of waist and hip circumference (cm).
Time frame: Measured three times, once at each in-clinic appointment (week 0, week 6, & week 12)
Differences in Multimodal Brain Signatures
Neuroimaging of a subset of participants brain via magnetic resonance imaging (MRI) procedure.
Time frame: Optional - Measured twice, once at baseline (week 0) and once at end of study (week 12) visit. Lasting approximately 1.5hours.
Plan to share: No — At this time there is no plan to make the de-identified data available for sharing with other researchers.
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Feb 2026, 31 months.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 31 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2026 → Feb 2026 and completion Jul 2027 → Feb 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
University of California, Los Angeles →